202.40EUR+0.30%Mkt Cap: 8.83B EURP/E: 95.34Last update: 2026-05-14
Financière de Tubize SA holds a stake in UCB, a biopharmaceutical company in Belgium. It focuses on the discovery and development of treatments for patients suffering from diseases affecting immune or central nervous sys…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)95.34
P/E (Forward)—
PEG1.24
P/B4.68
P/S—
EV/EBITDA-2973.86
EV/Revenue—
EPS (TTM)2.10
EPS (Forward)—
Cash Flow & Leverage
FCF Yield-0.05%
FCF Margin—
Operating CF-3.37M EUR
CapEx (TTM)—
Net Debt/EBITDA0.43
Net Debt-1.27M EUR
Technical
SMA 50211.54 (-4.3%)
SMA 200206.84 (-2.1%)
Beta0.37
S&P 52W Chg24.23%
Avg Vol (30d)22.87K
Avg Vol (10d)18.68K
Technical Indicators
RSI (14)44.6
MACD-4.0004
MACD Signal-4.5602
MACD Hist.+0.5598
BB Upper224.49 EUR
BB Middle205.10 EUR
BB Lower185.71 EUR
BB Width18.91%
ATR (14)5.889 EUR
Vol Ratio (20d)0.76x
52W Range
120.0063% of range250.50
52W High250.50 EUR
52W Low120.00 EUR
Profitability
Gross Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
Oper. Margin0.00%
ROE4.94%
ROA4.82%
Revenue Growth—
Earnings Growth—
Balance Sheet
Debt/Equity0.00
Current Ratio3.17
Quick Ratio2.56
Book Value/Sh42.36 EUR
Cash/Share0.0280 EUR
Dividends
Fwd Div Rate1.080 EUR
Trail. Div Rate1.080 EUR
Div. Yield0.54%
5Y Avg Yield0.86%
Payout Ratio49.66%
Ex-Div DateMay 7, 2026
Pay Date—
Splits
Last Split2:1
Split DateJun 17, 2005
Ownership
Shares Out.44.51M
Float20.71M
Insiders53.49%
Institutions7.79%
Analyst Consensus
Rating3.0 (Hold)
Target (Mean)286.00 EUR
Target Range286.00 EUR – 286.00 EUR
# Analysts1
Company
Market Cap8.83B EUR
Enterprise Value8.83B EUR
Revenue (TTM)—
Gross Profit-2.97M EUR
Net Income (TTM)93.23M EUR
Revenue/Share—
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees—
Last Price202.40 EUR
CountryBE
SectorHealthcare
IndustryBiotechnology
ISINBE0003823409